• 1. Which of the following best explains the mechanism of action of deucravacitinib?*
  • 2. Compared with first generation JAK inhibitors, selective TYK2 inhibition is expected to:*
  • 3. In the phase 3 POETYK PsA-1 and PsA-2 trials, what was the primary efficacy endpoint at week 16?*
  • 4. Which patient scenario best reflects an appropriate candidate for deucravacitinib based on the POETYK PsA-2 study design?*
  • What is your license?*

  • Please rate the extent to which this activity met the following objectives:

  • Learning Objectives
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • This educational activity will result in a change in my practice behavior.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

  • Attestation to time spent on activity:

    AcademicCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

  • AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.

  • Should be Empty: